Kiniksa Pharmaceuticals International (KNSA) Profit After Tax (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Profit After Tax came in at $25.4 million in Q2 2026, up 41.73% YoY from $17.9 million in Q2 2025, and up 12.57% on a QoQ basis from $22.6 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Profit After Tax (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Profit After Tax data on file, last reported at $25.4 million in Q2 2026.
- Quarterly Profit After Tax rose 41.73% year-over-year to $25.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $80.8 million (up 1590.13% YoY) and the FY2025 annual result came in at $59.1 million, up 236.39% from the prior year.
- Profit After Tax advanced to $25.4 million in Q2 2026, from $22.6 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $224.1 million in Q3 2022 to a low of -$25.2 million in Q1 2022.
- A 5-year average of $14.5 million and a median of $6.6 million in 2022 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax soared 832.01% — and 2024, when it plunged 135.64%.
- Tracing KNSA's Profit After Tax over 5 years: stood at $4.6 million in 2022, then soared by 453.1% to $25.3 million in 2023, then sank by 135.64% to -$9.0 million in 2024, then surged by 259.03% to $14.3 million in 2025, then soared by 77.49% to $25.4 million in 2026.
- The last three Profit After Tax figures came in at $25.4 million (Q2 2026), $22.6 million (Q1 2026), and $14.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 710.56 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn | 25.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.43 Mn |
| Mar 31, 2026 | 22.59 Mn |
| Dec 31, 2025 | 14.33 Mn |
| Sep 30, 2025 | 18.44 Mn |
| Jun 30, 2025 | 17.94 Mn |
| Mar 31, 2025 | 8.54 Mn |
| Dec 31, 2024 | -9.01 Mn |
| Sep 30, 2024 | -12.69 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -17.70 Mn |
| Dec 31, 2023 | 25.28 Mn |
| Sep 30, 2023 | -13.87 Mn |
| Jun 30, 2023 | 14.97 Mn |
| Mar 31, 2023 | -12.27 Mn |
| Dec 31, 2022 | 4.57 Mn |
| Sep 30, 2022 | 224.11 Mn |
| Jun 30, 2022 | -19.98 Mn |
| Mar 31, 2022 | -25.21 Mn |
| Dec 31, 2021 | -36.35 Mn |
| Sep 30, 2021 | -30.62 Mn |